ClinicalTrials.gg
CompletedNCT00225732Updated Jun 22, 2016Results posted

Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients

A Phase 3 interventional study of Normal saline as placebo comparator and Intravenous ibuprofen in Pain, sponsored by Cumberland Pharmaceuticals. Completed at 13 sites in 2 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-22.

Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
11th of 86
319 · median 100
Started
2005
the only one that year
Phase 3
22 of 86
none open now
Registered
1st of 86
by date
Lead sponsor
6 of 86
Cumberland Pharmaceuticals

Among the 86 studies testing ibuprofen in Pain, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 22 in phase 3, and was the 1st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The primary objective of this study of Caldolor (IV ibuprofen) administered to post-operative hospitalized adult patients every 6 hours for 48 hours is to determine the efficacy of Caldolor compared to placebo for the treatment of post-operative pain as measured by reduction in the requirement for the narcotic analgesic, morphine, post surgery

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Scheduled for elective abdominal hysterectomy surgery with anticipated need for post-operative I.V. morphine analgesia with anticipated use of ≥ 24 hours.
  2. Adequate IV access
  3. Anticipated hospital stay ≥ 24 hours

Exclusion criteria

Exclusion Criteria:

  1. Be unable to make a reliable self-report of pain intensity to pain relief
  2. Less than 18 years of age
  3. Greater than 70 years of age
  4. Use of NSAIDs within 12 hours prior to dosing
  5. Use of analgesics, muscle relaxants and sedatives less than 24 hours prior to CTM administration with the following exceptions: paracetamol (acetaminophen) can be administered until 6 hours prior to surgery; tramadol can be administered until midnight the evening prior to surgery; muscle relaxants working at the neuromuscular junction used for intubation and/or anesthesia administration for the surgical procedure prior to CTM administration; and sedatives (i.e., midazolam) used as a co-induction agent for the surgical procedure prior to CTM administration
  6. Patients taking warfarin, lithium, combination of ACE-inhibitors and furosemide
  7. Patients with anemia (active ) and/or a history or evidence of asthma or heart failure
  8. History of allergy or to any component of Caldolor, aspirin (or aspirin related products), NSAIDs, or COX-2 inhibitors
  9. Pregnant or nursing
  10. History of severe head trauma that required current hospitalization, intracranial surgery or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurysm or CNS mass lesion
  11. Weigh less than 30kg
  12. Have a history of congenital bleeding diathesis (eg hemophilia) or any active clinically significant bleeding, or have underlying dysfunction including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
  13. Have GI bleeding that required medical intervention within the previous 6 weeks (unless definitive surgery has been performed)
  14. Have a platelet count less than 30,000mm3 determined within the 28 days prior to surgery
  15. Pre-existing dependence on narcotics or known tolerance to opioids
  16. Inability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions and to return for the required assessments
  17. Refusal to provide written authorization for use and disclosure of protected health information
  18. Be on dialysis, have oliguria or calculated of less than 60 mL/min (calculated using the Cockcroft and Gault formula) determined within the 28 days prior to surgery
  19. Inability to achieve hemostasis or inability to close surgical incision, prior to Operating Room discharge
  20. Operative procedure includes organ transplant
  21. Pre or intra-operative procedure utilized for the prevention of pre- or post-operative pain (i.e. epidural or nerve blocks)
  22. Be receiving full dose anticoagulation therapy or Activated Protein C within 6 hours before dosing (Prophylaxis with subcutaneous heparin is acceptable)
  23. Have received another drug within the past 30 days
  24. Be otherwise unsuitable for the study in the opinion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
319 participants (actual)

Study arms

  • Active comparator
    intravenous ibuprofen

    Drug: Intravenous ibuprofen

  • Placebo comparator
    normal saline

    Other: Normal saline as placebo comparator

Interventions

  • OtherNormal saline as placebo comparator

    250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)

    Also known as: NS

  • 800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)

    Also known as: Caldolor

06

What researchers measure

Primary outcomes

  1. Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery

    Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 24 hour period post-surgery

    Time frame: 24 Hours

07

Results

Posted Sep 15, 2011

Participant flow

Participants were recruited from the medical practices and/or clinics of the investigator/sub-investigators.

Participant flow — Overall Study
MilestonePlacebo800 mg Intravenous Ibuprofen
Started153166
Completed153166
Not completed00

Outcome measures

PrimaryChange in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery

Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 24 hour period post-surgery

Time frame:
24 Hours
Reported as:
Least squares mean · milligrams
Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery
milligramsPlacebo800 mg Intravenous Ibuprofen
Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery57.0 ± 2.448.7 ± 2.3

Adverse events

Collected over 14 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/153 (3.9%)149/153 (97.4%)
800 mg Intravenous Ibuprofen—12/166 (7.2%)150/166 (90.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlacebo800 mg Intravenous Ibuprofen
IleusGastrointestinal disorders1/1533/166
AtelectasisRespiratory, thoracic and mediastinal disorders2/1530/166
Oxygen saturation decreasedInvestigations1/1530/166
Peritoneal HemorrhageGastrointestinal disorders1/1530/166
CholecystitisHepatobiliary disorders1/1530/166
Abdominal AbscessInfections and infestations0/1531/166
Peritoneal abscessInfections and infestations0/1531/166
Wound drainageSurgical and medical procedures0/1531/166
TachycardiaCardiac disorders0/1531/166
Wound DihisenceInjury, poisoning and procedural complications0/1531/166
Most frequent other events
Most frequent other events
EventPlacebo800 mg Intravenous Ibuprofen
NauseaGastrointestinal disorders85/15379/166
FlatulenceGastrointestinal disorders34/15342/166
PruritisSkin and subcutaneous tissue disorders33/15332/166
ConstipationGastrointestinal disorders21/15313/166
VomitingGastrointestinal disorders12/15315/166
HeadacheNervous system disorders11/15310/166
PyrexiaGeneral disorders9/1536/166
Body temperature increasedInvestigations7/1537/166

Baseline characteristics

Age, Customized
Age, Customized(participants)Placebo800 mg Intravenous IbuprofenTotal
Less than or equal to 45 years104110214
45 to 70 years of age4956105
Sex: Female, Male
Sex: Female, Male(Participants)Placebo800 mg Intravenous IbuprofenTotal
Female153166319
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo800 mg Intravenous IbuprofenTotal
Caucasian5271123
Black or African American9184175
Hispanic81119
Asian000
Other202
Region of Enrollment
Region of Enrollment(participants)Placebo800 mg Intravenous IbuprofenTotal
United States153166319
Weight
Weight(Kilograms)Placebo800 mg Intravenous IbuprofenTotal
Less than or equal to 75 kilograms5761118
Greater than 75 kilograms96105201
08

Study locations

13 sites
  • Cooper Green Hospital / Jefferson Clinic
    Birmingham, Alabama 35233, United States
  • Medical Center East / Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
  • Springhill Hospital / Wilmax Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Mobile Infirmary Medical Center / Wilmax Clinical Research, Inc.
    Mobile, Alabama 36652-2144, United States
  • Jackson Hospital / Drug Research and Analysis Corporation
    Montgomery, Alabama 36106, United States
  • Baptist Medical Center South / Drug Research and Analysis Corporation
    Montgomery, Alabama 36111, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Valley OB/GYN
    Colton, California 92324, United States
  • Research Support Personnel LLC
    Wichita, Kansas 67208, United States
  • Chandler Medical Center; Ken Muse Research
    Lexington, Kentucky 40536, United States
  • Comprehensive Pain Specialists
    Hendersonville, Tennessee 37075, United States
  • Health First Medical Group
    Fort Worth, Texas 76135, United States
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
09

References and documents

Publications

  • Southworth S, Peters J, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther. 2009 Sep;31(9):1922-35. doi: 10.1016/j.clinthera.2009.08.026. PubMed 19843482 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2005
First posted
Sep 26, 2005
Start
Jan 2005
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Sep 15, 2011
Last update
Jun 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00225732
Responsible party
Sponsor
First posted
Sep 26, 2005
Start date
Jan 2005
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Sep 15, 2011
Last update
Jun 22, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion